Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Liabilities: 2024-2025

Historic Total Liabilities for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $406.8 million.

  • Kura Oncology's Total Liabilities rose 638.82% to $406.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.8 million, marking a year-over-year increase of 638.82%. This contributed to the annual value of $346.5 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Total Liabilities is $406.8 million, which was up 7.93% from $376.9 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Total Liabilities ranged from a high of $406.8 million in Q3 2025 and a low of $48.8 million during Q1 2024.
  • Moreover, its 2-year median value for Total Liabilities was $346.5 million (2024), whereas its average is $237.5 million.
  • Data for Kura Oncology's Total Liabilities shows a peak YoY surged of 676.99% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Total Liabilities stood at $346.5 million in 2024, then skyrocketed by 638.82% to $406.8 million in 2025.
  • Its Total Liabilities stands at $406.8 million for Q3 2025, versus $376.9 million for Q2 2025 and $379.4 million for Q1 2025.